H. Suganami

发表

Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells.

T. Kodama, S. Morikawa, T. Hamakubo, 2000, Journal of atherosclerosis and thrombosis.

QT PRODACT: sensitivity and specificity of the canine telemetry assay for detecting drug-induced QT interval prolongation.

H. Suganami, Hiroyasu Miyazaki, Hiroyuki Watanabe, 2005, Journal of pharmacological sciences.

Statistical Screening Method for Genetic Factors Influencing Susceptibility to Common Diseases in a Two-Stage Genome-Wide Association Study

N. Laird, Teruhiko Yoshida, H. Suganami, 2009, Statistical applications in genetics and molecular biology.

Effects of a novel selective peroxisome proliferator‐activated receptor‐α modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance

S. Yamashita, H. Arai, E. Araki, 2018, Journal of diabetes investigation.

Role of fatty liver in the association between obesity and reduced hepatic insulin clearance.

K. Fujihara, H. Sone, S. Kodama, 2017, Diabetes & metabolism.

Influence of an SGLT2 inhibitor, tofogliflozin, on the resting heart rate in relation to adipose tissue insulin resistance

K. Fujihara, H. Sone, K. Kaku, 2020, Diabetic medicine : a journal of the British Diabetic Association.

Basal insulin secretion capacity predicts the initial response and maximum levels of beta‐hydroxybutyrate during therapy with the sodium‐glucose co‐transporter‐2 inhibitor tofogliflozin, in relation to weight loss

K. Kaku, H. Suganami, K. Nunoi, 2019, Diabetes, obesity & metabolism.

Attenuation of weight loss through improved antilipolytic effect in adipose tissue via the SGLT2 inhibitor tofogliflozin.

K. Fujihara, H. Sone, Shiro Tanaka, 2019, The Journal of clinical endocrinology and metabolism.

Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator‐activated receptor α modulator (SPPARMα), versus placebo in patients with non‐alcoholic fatty liver disease

Y. Eguchi, A. Nakajima, R. Loomba, 2021, Alimentary pharmacology & therapeutics.

Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin Combination

S. Yamashita, H. Arai, E. Araki, 2019, International journal of molecular sciences.

Long‐term safety and efficacy of the sodium–glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon‐like peptide‐1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52‐week open‐label, multicenter, post‐marketing clinical study

Y. Terauchi, M. Senda, M. Tamura, 2019, Journal of diabetes investigation.

Sodium–glucose cotransporter 2 inhibitor, tofogliflozin, shows better improvements of blood glucose and insulin secretion in patients with high insulin levels at baseline

K. Tobe, K. Kaku, H. Suganami, 2017, Journal of diabetes investigation.

Correlation between Climate and Crime in Eastern Tokyo

H. Suganami, H. Ikegaya, 2008 .

Efficacy and Safety of Pitavastatin in Children and Adolescents with Familial Hypercholesterolemia in Japan and Europe

M. Harada‐Shiba, A. Ohtake, H. Suganami, 2017, Journal of atherosclerosis and thrombosis.

Effects of pemafibrate (K-877) on cholesterol efflux capacity and postprandial hyperlipidemia in patients with atherogenic dyslipidemia.

S. Yamashita, H. Arai, E. Araki, 2018, Journal of clinical lipidology.

Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment

S. Yamashita, H. Arai, E. Araki, 2019, International journal of molecular sciences.

Restricted mean survival time as a summary measure of time‐to‐event outcome

H. Suganami, Akira Wakana, T. Tanase, 2020, Pharmaceutical statistics.

Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin

Asuka Morita, P. Jutabha, N. Anzai, 2018, Diabetes, obesity & metabolism.

The Plasma Concentration and Pharmacokinetic Parameters of Pemafibrate Did Not Increase in a Creatinine Clearance-Dependent Manner

D. Hosford, H. Suganami, G. Gordon, 2018, Atherosclerosis Supplements.

A Pooled Analysis of Pemafibrate Phase II/III Clinical Trials Indicated Significant Improvement in Glycemic and Liver Function-related Parameters

S. Yamashita, H. Arai, E. Araki, 2018, Atherosclerosis Supplements.

Pemafibrate Minimally Affected the Systemic Exposure of Statins, and Vice Versa, in Healthy Male Volunteers

H. Suganami, N. Hounslow, M. Nakamura, 2018, Atherosclerosis Supplements.

Pemafibrate Has High Bioavailability and is Principally Excreted via the Liver

H. Suganami, N. Hounslow, S. Mair, 2018, Atherosclerosis Supplements.

Efficacy and Safety of Pitavastatin in Japanese Male Children with Familial Hypercholesterolemia.

M. Harada‐Shiba, A. Ohtake, H. Suganami, 2016, Journal of atherosclerosis and thrombosis.

Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study

Y. Terauchi, Y. Iwamoto, H. Watada, 2014, Cardiovascular Diabetology.

Efficacy and safety of pemafibrate in people with type 2 diabetes and elevated triglyceride levels: 52‐week data from the PROVIDE study

S. Yamashita, H. Maegawa, J. Satoh, 2019, Diabetes, obesity & metabolism.

Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, randomized controlled trials

Y. Terauchi, Y. Iwamoto, H. Watada, 2014, Expert opinion on pharmacotherapy.

Predictors of the response of HbA1c and body weight after SGLT2 inhibition.

K. Fujihara, H. Sone, K. Kaku, 2017, Diabetes & metabolism.

Association of estimated plasma volume and weight loss after long‐term administration and subsequent discontinuation of the sodium‐glucose cotransporter‐2 inhibitor tofogliflozin

K. Fujihara, H. Sone, Takaho Yamada, 2021, Diabetes, obesity & metabolism.

Dipeptidyl peptidase‐4 inhibitor, anagliptin, alters hepatic insulin clearance in relation to the glycemic status in Japanese individuals with type 2 diabetes

K. Fujihara, H. Sone, Shiro Tanaka, 2021, Journal of diabetes investigation.

Stimulation of cell proliferation and autoregulation of elastin expression by elastin peptide VPGVG in cultured chick vascular smooth muscle cells

H. Suganami, S. Tajima, H. Wachi, 1995, FEBS letters.

One‐year clinical evaluation of 0.4% ripasudil (K‐115) in patients with open‐angle glaucoma and ocular hypertension

M. Araie, H. Abe, H. Suganami, 2016, Acta ophthalmologica.

Additive Intraocular Pressure-Lowering Effects of the Rho Kinase Inhibitor Ripasudil (K-115) Combined With Timolol or Latanoprost: A Report of 2 Randomized Clinical Trials.

M. Araie, H. Abe, H. Suganami, 2015, JAMA ophthalmology.

Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial.

S. Yamashita, H. Arai, E. Araki, 2017, Journal of clinical lipidology.

Current Practice in Japan for the Prevention and Treatment of Missing Data in Confirmatory Clinical Trials

Shiro Tanaka, H. Suganami, Satoru Fukinbara, 2014, Therapeutic innovation & regulatory science.

Morphological Changes of Human Corneal Endothelial Cells after Rho-Associated Kinase Inhibitor Eye Drop (Ripasudil) Administration: A Prospective Open-Label Clinical Study

N. Koizumi, H. Suganami, S. Kinoshita, 2015, PloS one.

Intra‐ocular pressure‐lowering effects of a Rho kinase inhibitor, ripasudil (K‐115), over 24 hours in primary open‐angle glaucoma and ocular hypertension: a randomized, open‐label, crossover study

Toshihiro Inoue, Haruki Abe, Makoto Araie, 2015, Acta ophthalmologica.

Effects of sodium‐glucose cotransporter 2 inhibitor, tofogliflozin, on the indices of renal tubular function in patients with type 2 diabetes

K. Kaku, H. Suganami, K. Nunoi, 2018, Endocrinology, diabetes & metabolism.

The confidence interval of allelic odds ratios under the Hardy-Weinberg disequilibrium

Teruhiko Yoshida, H. Sakamoto, K. Yoshimura, 2006, Journal of Human Genetics.

Regional distribution of two related Northeast Asian genotypes of JC virus, CY-a and -b: implications for the dispersal of Northeast Asians.

T. Kitamura, H. Suganami, Jung-Chul Kim, 2004, Microbes and infection.

Genetic diversity of JC virus in the Saami and the Finns: implications for their population history.

T. Vesikari, T. Kitamura, H. Suganami, 2005, American journal of physical anthropology.

Renal effects of a sodium‐glucose cotransporter 2 inhibitor, tofogliflozin, in relation to sodium intake and glycaemic status

K. Kaku, H. Suganami, K. Nunoi, 2019, Diabetes, obesity & metabolism.

Association of increased hepatic insulin clearance and change in serum triglycerides or β‐hydroxybutyrate concentration via the sodium/glucose‐cotransporter 2 inhibitor tofogliflozin

K. Fujihara, H. Sone, K. Furukawa, 2019, Diabetes, obesity & metabolism.

The SGLT2 Inhibitor Tofogliflozin Reduces Weight in People with Type 2 Diabetes due to Fluid Loss Initially and to Lipolysis in Late

T. Takamura, K. Kaku, H. Suganami, 2018, Diabetes.

Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia.

S. Yamashita, H. Arai, E. Araki, 2017, Atherosclerosis.

Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial.

S. Yamashita, T. Kodama, H. Arai, 2016, Atherosclerosis.

Predictors of haemoglobin levels and of changes in these levels, focusing on anaemia and polycythaemia after administration of the sodium‐glucose cotransporter‐2 inhibitor tofogliflozin

K. Fujihara, H. Sone, Takaho Yamada, 2022, Diabetes, obesity & metabolism.

Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial

S. Yamashita, H. Maegawa, J. Satoh, 2018, Diabetes Care.

Utilization of bone impedance for age estimation in postmortem cases.

T. Kubo, Atsushi Nishida, H. Suganami, 2015, Journal of forensic and legal medicine.

Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double‐blind placebo‐controlled clinical trials

S. Yamashita, H. Arai, E. Araki, 2021, Cardiovascular Diabetology.

Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial

S. Yamashita, H. Arai, E. Araki, 2018, Journal of atherosclerosis and thrombosis.

Current Practice on Multiplicity Adjustment and Sample Size Calculation in Multi-arm Clinical Trials: An Industry Survey in Japan

H. Suganami, K. Sakamaki, Akira Wakana, 2016, Therapeutic innovation & regulatory science.

QT PRODACT: inter-facility variability in electrocardiographic and hemodynamic parameters in conscious dogs and monkeys.

H. Suganami, Keiji Yamamoto, N. Shimizu, 2005, Journal of pharmacological sciences.

Efficacy and Safety of Pitavastatin/Ezetimibe Fixed-Dose Combination vs. Pitavastatin: Phase III, Double-Blind, Randomized Controlled Trial.

K. Tsujita, K. Yokote, H. Suganami, 2023, Journal of atherosclerosis and thrombosis.

Efficacy and Safety of K-877 (Pemafibrate), a Selective PPARα Modulator, in European Patients on Statin Therapy.

G. Hovingh, P. Bogdański, R. Libis, 2022, Diabetes care.

Multiplicity Adjustment and Sample Size Calculation in Clinical Trials with Multiple Endpoints: An Industry Survey of Current Practices in Japan

H. Suganami, K. Sakamaki, S. Tsuchiya, 2020, Therapeutic Innovation & Regulatory Science.

Crossover Randomized Study of Pharmacologic Effects of Ripasudil–Brimonidine Fixed-Dose Combination Versus Ripasudil or Brimonidine

N. Koizumi, M. Aihara, H. Suganami, 2023, Advances in therapy.

O R I G I N a L I N V E S T I G a T I O N Open Access

Y. Terauchi, Y. Iwamoto, H. Watada, 2022 .